Literature DB >> 25840795

Synthesis, crystal structures, and urease inhibition of an acetohydroxamate-coordinated oxovanadium(V) complex derived from N'-(3-bromo-2-hydroxybenzylidene)-4-methoxybenzohydrazide.

Dan Qu1, Fang Niu1, Xinlu Zhao1, Ke-Xiang Yan2, Yu-Ting Ye1, Jia Wang1, Mei Zhang1, Zhonglu You3.   

Abstract

A new benzohydrazone compound N'-(3-bromo-2-hydroxybenzylidene)-4-methoxybenzohydrazide (H₂L) was prepared. Reaction of H₂L and acetohydroxamic acid (HAHA) with VO(acac)₂ in methanol gave the complex [VOL(AHA)]. Both H₂L and the oxovanadium complex were characterized by elemental analysis, IR, UV-vis and (1)H NMR spectra, and single crystal X-ray diffraction. H₂L was also characterized by high-resolution mass spectrum. Thermal analysis of the oxovanadium complex was carried out. The benzohydrazone ligand, in its dianionic form, coordinates to V atom through the phenolate oxygen, imino nitrogen and enolate oxygen. The acetohydroxamic acid coordinates to V atom through the carbonyl oxygen and deprotonated hydroxyl oxygen. The V atom is in octahedral coordination. H₂L, HAHA and the oxovanadium complex were tested for their urease inhibitory activities. The percent inhibition at concentration of 100 μmol·L(-1) on Helicobacter pylori urease is 78% for the oxovanadium complex. The IC₅₀ value for the complex is 36.5 μmol·L(-1). Molecular docking study was performed to study the inhibition.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Benzohydrazone; Crystal structure; Oxovanadium(V) complex; Urease inhibition

Mesh:

Substances:

Year:  2015        PMID: 25840795     DOI: 10.1016/j.bmc.2015.03.036

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  Anticancer Activity of Urease Mimetic Cobalt (III) Complexes on A549-Lung Cancer Cells: Targeting the Acidic Microenvironment.

Authors:  Bhawna Uprety; Rahul Chandran; Charmaine Arderne; Heidi Abrahamse
Journal:  Pharmaceutics       Date:  2022-01-17       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.